SDGR Overview

Schrodinger, Inc. is a developer of a physics-based computational platform that enables discovery of molecules for drug development and materials applications. The Company's segments include Software and Drug Discovery. The Software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in the material science industries. The Drug Discovery segment is focused on building a portfolio of preclinical and clinical drug programs, internally and through collaborations. It offers WaterMap, which characterizes the locations and energetics of water molecules occupying the binding site of, or solvating, a target protein. It also offers FEP+, which is a free energy calculation software which can be used to replace the central core of earlier known tight binding molecules to identify potent molecules unavailable in library collections. It can also be used to calculate absolute binding affinities.

Wall Street analysts forecast SDGR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SDGR is21.83 USD with a low forecast of 18.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Schrodinger Inc revenue for the last quarter amounts to 58.59M USD, decreased -1.62

Schrodinger Inc. EPS for the last quarter amounts to -0.81 USD, decreased -1.22

Schrodinger Inc (SDGR) has 850 emplpoyees as of July 08 2026.

Today SDGR has the market capitalization of 1.23B USD.